Safety Endpoints
Kaletra and interferon alfa-2b therapy was well tolerated by the exposed group without premature discontinuation secondary to adverse effects. There were no significant differences among the 3 group in the incidence of nausea, diarrhea, rash, leukopenia, neutropenia, anemia, thrombocytopenia, increased creatinine, and et al (Table 2). However, the incidence of increased creatine kinase over the therapy course was higher in the exposed group (15.91% in interferon alfa-2b group vs 20.90% in Kaletra/ interferon alfa-2b group) than in the standard care group (0), despite without statistical difference. Aside from anemia and increased bilirubin, the occurrence of adverse effects were lower in standard care group than in therapy groups.